Upstream Bio

UPBPhase 2

Upstream Bio is focused on developing verekitug, the only known clinical-stage antagonist of the TSLP receptor, to address chronic respiratory diseases driven by inflammation. The company has completed Phase 2 trials in severe asthma and CRSwNP and has an ongoing Phase 2 trial in COPD. Led by an experienced team with deep industry and clinical expertise, Upstream Bio aims to provide a differentiated, upstream therapeutic approach for patients underserved by current standards of care.

Market Cap

$468.5M

Focus

AntibodiesBiologics

UPB · Stock Price

USD 8.6713.33 (-60.59%)

Historical price data

AI Company Overview

Technology Platform

Monoclonal antibody platform targeting the TSLP receptor to inhibit upstream inflammatory signaling, with potential for broad efficacy across multiple cytokine pathways.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
Verekitug + Placebo	Severe Asthma	Phase 2
Verekitug	Chronic Obstructive Pulmonary Disease	Phase 2
Verekitug (UPB-101) + Placebo	Severe Asthma	Phase 2
Verekitug (UPB-101) + Placebo	Chronic Rhinosinusitis With Nasal Polyps	Phase 2
UPB-101	Healthy	Phase 1

Funding History

Total raised: $200M

Series A$200MOrbiMedJul 15, 2022

Opportunities

Expanding verekitug into additional TSLP-mediated inflammatory diseases beyond the initial respiratory focus represents a significant pipeline expansion opportunity.

Positive Phase 2 data in COPD could position the asset as a first-in-class biologic for a large, underserved patient population.

The company's public status provides a platform for potential partnerships or strategic acquisitions.

Risk Factors

The company is a single-asset entity, making it highly vulnerable to clinical setbacks with verekitug.

It faces intense competition from established biologics in asthma and CRSwNP, requiring clear differentiation.

As a pre-revenue public company, it is dependent on volatile capital markets to fund expensive late-stage development.

Competitive Landscape

Primary competitor is AstraZeneca's tezepelumab (anti-TSLP) in severe asthma. Verekitug differentiates by targeting the TSLP receptor instead of the ligand, potentially offering mechanistic advantages. It also competes with a range of downstream cytokine-targeting biologics (anti-IL-4/13, anti-IL-5, anti-IgE) from major pharma companies.

Publications

Patents

Pipeline